{"DataElement":{"publicId":"3855565","version":"1","preferredName":"Acute Leukemia Or Blast Phase Chronic Myelogenous Leukemia Cytogenetic Response Status","preferredDefinition":"Text term to describe the acute leukemia or blast phase chronic myelogenous leukemia disease status based on cytogenetic evaluation.","longName":"ALCMLBC_CYTO_RESP_ST","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3853613","version":"1","preferredName":"Acute Leukemia Or Blast Phase Chronic Myelogenous Leukemia Cytogenetic Response","preferredDefinition":"A clonal (malignant) hematopoietic disorder affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).  According to the type of blasts present, acute leukemias are classified as acute myeloid leukemia (AML) and precursor lymphoblastic or acute lymphoblastic leukemia (ALL)._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An advanced phase of chronic myelogenous leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001)._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"3853611v1.0:3853590v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3853611","version":"1","preferredName":"Acute Leukemia Or Blast Phase Chronic Myelogenous Leukemia Response","preferredDefinition":"A clonal (malignant) hematopoietic disorder affecting the bone marrow and the peripheral blood. The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts). According to the type of blasts present, acute leukemias are classified as acute myeloid leukemia (AML) and precursor lymphoblastic or acute lymphoblastic leukemia (ALL).:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:An advanced phase of chronic myelogenous leukemia.  It is characterized a. by the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or b. an extramedullary proliferation of blasts, and/or c. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C9300:C37998:C9110:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C9110","definition":"An advanced phase of chronic myeloid leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CB76BD-D156-2626-E040-BB89AD436DA7","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853590","version":"1","preferredName":"Cytogenetic Analysis Evaluation","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C18280:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CB76BD-D0EF-2626-E040-BB89AD436DA7","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3CB76BD-D164-2626-E040-BB89AD436DA7","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3854981","version":"1","preferredName":"Acute Leukemia/CML (BC) Cytogenetic Analysis Response Status","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"ALCMLBC_CYTGN_RSP_ST","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cytogenetic Complete Remission (CRc)","valueDescription":"Cytogenetic Analysis Complete Remission","ValueMeaning":{"publicId":"3854980","version":"1","preferredName":"Cytogenetic Analysis Complete Remission","longName":"3854980","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-882B-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SOKKERL","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3DF4512-8883-A83E-E040-BB89AD431C6D","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","deletedIndicator":"No"},{"value":"Cytogenetic Relapse","valueDescription":"Cytogenetic Analysis Recurrent Disease","ValueMeaning":{"publicId":"3854979","version":"1","preferredName":"Cytogenetic Analysis Recurrent Disease","longName":"3854979","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-8808-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3DF4512-888D-A83E-E040-BB89AD431C6D","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","deletedIndicator":"No"},{"value":"Not Evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3DF4512-88A1-A83E-E040-BB89AD431C6D","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","deletedIndicator":"No"},{"value":"Persistent Cytogenetic Abnormality","valueDescription":"Persistent Cytogenetic Abnormality","ValueMeaning":{"publicId":"4571372","version":"1","preferredName":"Persistent Cytogenetic Abnormality","longName":"4571372","preferredDefinition":"Retained; never-ceasing.: An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Persistent","conceptCode":"C43623","definition":"Retained; never-ceasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytogenetic Abnormality","conceptCode":"C2950","definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06FECA4E-7EF5-9714-E050-BB89AD432ED0","latestVersionIndicator":"Yes","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06FECA4E-7F1A-9714-E050-BB89AD432ED0","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"ONEDATA","dateModified":"2014-11-03","deletedIndicator":"No"},{"value":"Not Assessed","valueDescription":"No Assessment","ValueMeaning":{"publicId":"2768467","version":"1","preferredName":"No Assessment","longName":"2768467","preferredDefinition":"The non-affirmative response to a question.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52C71733-4814-2BF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"070018CF-5B1A-5049-E050-BB89AD43421B","beginDate":"2013-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"ONEDATA","dateModified":"2014-11-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3865326","version":"1","preferredName":"Cytogenetic Analysis Response Status","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C18280:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4E2F160-F25E-E72E-E040-BB89AD430752","latestVersionIndicator":"Yes","beginDate":"2013-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3DF4512-886E-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3813676","version":"1","longName":"Response CRF","context":"NCIP"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"3813675","version":"1","longName":"Response","context":"NCI Standards"}]},{"publicId":"7434158","version":"1","longName":"CTEP CDISC Harmonization","context":"CTEP","ClassificationSchemeItems":[{"publicId":"7590138","version":"1","longName":"CTEP CDISC Response","context":"CTEP"}]}],"AlternateNames":[{"name":"RS_RSORRES_CYTORESP_CMLBC","type":"CTEP CDISC CDE","context":"CTEP"}],"ReferenceDocuments":[{"name":"Cytogenetic status (Acute Leu","type":"Preferred Question Text","description":"Cytogenetic status (Acute Leukemia/CML (BC))","url":null,"context":"NCI Standards"},{"name":"Prior Question Text","type":"Standard Alternate Question Text","description":"Cytogenetic Status (Acute Leukemia/CML (BC))","url":null,"context":"NCI Standards"},{"name":"CTEP Text 1","type":"Alternate Question Text","description":"What was the CML (BC) cytogenetic response?","url":null,"context":"CTEP"},{"name":"CTEP Text 2","type":"Alternate Question Text","description":"CML (BC) cytogenetic response","url":null,"context":"CTEP"}],"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"E3F3FD8B-3500-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"CLOHNES","dateModified":"2022-10-21","changeDescription":"8/23/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created per request by CRF Harmonization Response WG.","administrativeNotes":"10/21/22 added 1 alt name, 2 AQTs, 1 classification for the CTEP CDISC Harmonization project;","unresolvedIssues":null,"deletedIndicator":"No"}}